Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor

por Furuhashi, Masato, Matsumoto, Megumi, Hiramitsu, Shinya, Omori, Akina, Tanaka, Marenao, Moniwa, Norihito, Yoshida, Hideaki, Ishii, Junnichi, Miura, Tetsuji
Publicado 2016

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

por Furuhashi, Masato, Hiramitsu, Shinya, Mita, Tomohiro, Omori, Akina, Fuseya, Takahiro, Ishimura, Shutaro, Watanabe, Yuki, Hoshina, Kyoko, Matsumoto, Megumi, Tanaka, Marenao, Moniwa, Norihito, Yoshida, Hideaki, Ishii, Junnichi, Miura, Tetsuji
Publicado 2016

Serum FABP5 concentration is a potential biomarker for residual risk of atherosclerosis in relation to cholesterol efflux from macrophages

por Furuhashi, Masato, Ogura, Masatsune, Matsumoto, Megumi, Yuda, Satoshi, Muranaka, Atsuko, Kawamukai, Mina, Omori, Akina, Tanaka, Marenao, Moniwa, Norihito, Ohnishi, Hirofumi, Saitoh, Shigeyuki, Harada-Shiba, Mariko, Shimamoto, Kazuaki, Miura, Tetsuji
Publicado 2017